Hung Tran, M.D.

(877) 460-4673
Hung Tran, M.D.
Pediatric Oncologist
Clinical Expertise

Pediatric Oncology

Academic Appointments

Associate Clinical Professor, Division of Oncology, Department of Pediatrics

Hung Tran, M.D. is a pediatric oncologist and an associate clinical professor in the Department of Pediatrics at City of Hope® Cancer Center Duarte. He cares for children, adolescents, and young adults diagnosed with a wide range of cancer types, including musculoskeletal and solid tumor malignancies.

After medical school, he chose to pursue pediatric oncology because, as he notes, “it requires a dedication to scientific discovery, paired with our utmost humanity, to do all we can for a child facing cancer.” A physician who is committed to bringing the latest research advances into clinical practice, Dr. Tran has served as a principal investigator on several grant-funded research projects and published in leading journals, such as Clinical Cancer Research and the Journal of Pediatrics.

Dr. Tran earned his medical degree from the Johns Hopkins School of Medicine in Baltimore, Maryland. He completed his internship and residency at UCSF Benioff Children’s Hospital in Oakland, California, followed by a pediatric hematology/oncology fellowship at Children’s Hospital Los Angeles.

Before joining City of Hope, Dr. Tran cared for patients at the Children’s Hospital of Orange County and served as the Medical Director of Quality and Patient Safety for the Division of Oncology. Dr. Tran also has extensive leadership experience, including previously serving as Regional Lead for the Pediatric Hematology Oncology for Kaiser Permanente -Northern California.

Outside of the clinic, Dr. Tran enjoys hiking in the San Gabriel Mountains and participating in cultural activities throughout the community.

Location

Education & Experience

Education

  • 1999, Bachelor of Science, cum laude, Molecular Biology, Columbia University, New York, New York
  • 2004, Doctor of Medicine (M.D.), Johns Hopkins University School of Medicine, Baltimore, Maryland

Internship

  • 2004–2005, Internship, UCSF Benioff Children’s Hospital – Oakland, Oakland, California

Residency

  • 2005–2007, Residency, UCSF Benioff Children’s Hospital – Oakland, Oakland, California

Fellowship

  • 2008–2011, Pediatric Hematology‑Oncology Fellowship, Children’s Hospital Los Angeles, Keck School of Medicine of USC, Los Angeles, California

Professional Experience

  • 2026-present, Associate Clinical Professor, Division of Oncology, Department of Pediatrics, City of Hope, Duarte, California
  • 2025–present, Health Sciences Associate Professor, Clinical Pediatrics, University of California, Irvine School of Medicine, Irvine, California
  • 2023–present, Medical Director of Quality and Patient Safety, Division of Oncology,
    Children’s Hospital of Orange County, Orange, California
  • 2023–2026, Pediatric Oncologist, Children’s Hospital of Orange County, Orange, California
  • 2017–2023, Medical Director, Division of Pediatric Hematology and Oncology, Kaiser Permanente Oakland Medical Center; Regional Lead, Pediatric Hematology‑Oncology, Northern California; Pediatric Hematology‑Oncologist, The Permanente Medical Group, Northern California
  • 2018–2023, Volunteer Faculty, Department of Pediatrics, Division of Pediatric Hematology/Oncology, University of California, San Francisco (UCSF), San Francisco, California
  • 2011–2015, Assistant Professor of Clinical Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California
  • 2011–2015, Assistant Medical Director, New Approaches to Neuroblastoma Therapies (NANT) Research Consortium
  • 2011–2015, Pediatric Hematology‑Oncologist, Children’s Hospital Los Angeles, Los Angeles, California

Publications

  • Martin SD, Davis ES, Dai C, et al. Pediatric Oncology COVID-19 Case Consortium. Clinical features and risk factors associated with multisystem inflammatory syndrome in children with cancer and COVID‑19. JAMA Oncology. 2023 Aug 1;9(8):1108‑1112. doi: 10.1001/jamaoncol.2023.0525
  • Shackleford GM, Mahdi MY, Moats RA, Hawes D, Tran HC, Finlay JL, Hoang TQ, Meng EF, Erdreich‑Epstein A. Continuous and bolus intraventricular topotecan prolong survival in a mouse model of leptomeningeal medulloblastoma. PLoS One. 2019 Jan 4;14(1):e0206394. doi: 10.1371/journal.pone.0206394
  • Marachelian A, Villablanca JG, Liu WC, Liu B, Goodarzian F, Lai HA, Shimada H, Tran HC, Parra JA, Gallego R, Bedrossian N, Young S, Czarnecki S, Kennedy R, Weiss BD, Goldsmith K, Granger M, Matthay KK, Groshen S, Asgharzadeh S, Sposto R, Seeger RC. Expression of five neuroblastoma genes in bone marrow or blood of patients with relapsed/refractory neuroblastoma provides a new biomarker for disease and prognosis. Clinical Cancer Research. 2017 Sep 15;23(18):5374‑5383. doi: 10.1158/1078‑0432.CCR‑16‑2647
  • Tran HC, Wan Z, Sheard MA, Sun J, Jackson JR, Malvar J, Xu Y, Wang L, Sposto R, Kim ES, Asgharzadeh S, Seeger RC. TGFβR1 blockade with galunisertib (LY2157299) enhances anti‑neuroblastoma activity of the anti‑GD2 antibody dinutuximab (ch14.18) with natural killer cells. Clinical Cancer Research. 2017 Feb 1;23(3):804‑813. doi: 10.1158/1078‑0432.CCR‑16‑1743
  • Jackson JR, Tran HC, Stein JE, Shimada H, Patel AM, Marachelian A, Kim ES. The clinical management and outcomes of cervical neuroblastic tumors. Journal of Surgical Research. 2016 Jul;204(1):109‑113. doi: 10.1016/j.jss.2016.04.030
  • Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and doxorubicin for relapsed or refractory high‑risk neuroblastoma. Pediatric Hematology and Oncology. 2015 Feb;32(1):26‑31. doi: 10.3109/08880018.2014.983624
  • Polishchuk AL, Li R, Hill‑Kayser C, Little A, Hawkins RA, Hamilton J, Lau M, Tran HC, Strahlendorf C, Lemons RS, Weinberg V, Matthay KK, DuBois SG, Marcus KJ, Bagatell R, Haas‑Kogan DA. Likelihood of bone recurrence in prior sites of metastasis in patients with high‑risk neuroblastoma. International Journal of Radiation Oncology Biology Physics. 2014 Jul 15;89(4):839‑845. doi: 10.1016/j.ijrobp.2014.04.004
  • Tran HC, Gardner S, Weiner HL, Liebes LF, Finlay JL. Pilot study assessing a seven‑day continuous intrathecal topotecan infusion for recurrent or progressive leptomeningeal metastatic cancer. Journal of Oncology Pharmacy Practice. 2014 Jun;20(3):229‑232. doi: 10.1177/1078155213494940
  • Shah R, Tran HC, Randolph L, Mascarenhas L, Venkatramani R. Hepatoblastoma in a 15‑month‑old female with trisomy 13. American Journal of Medical Genetics Part A. 2014 Feb;164A(2):472‑475. doi: 10.1002/ajmg.a.36271
  • Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC. Lenalidomide overcomes suppression of human natural killer cell anti‑tumor functions by neuroblastoma microenvironment‑associated IL‑6 and TGFβ1. Cancer Immunology, Immunotherapy. 2013 Oct;62(10):1637‑1648. doi: 10.1007/s00262‑013‑1466‑y
  • Boztug K, Rosenberg PS, Dorda M, Banka S, Moulton T, Curtin J, Rezaei N, Corns J, Innis JW, Avci Z, Tran HC, et al. Extended spectrum of human glucose‑6‑phosphatase catalytic subunit 3 deficiency: Novel genotypes and phenotypic variability in severe congenital neutropenia. Journal of Pediatrics. 2012 Apr;160(4):679‑683. doi: 10.1016/j.jpeds.2011.09.019